The natural products beauveriolide I and III: a new class of beta-amyloid-lowering compounds.
Attacking Alzheimer's by ACAT: The aggregation of beta-amyloid peptides, especially Abeta(42), into senile plaques is a hallmark of Alzheimer's disease (AD). We show that the fungal natural products beauveriolides I and III can potently decrease Abeta secretion from cells expressing human amyloid precursor protein; this offers a potential new scaffold for the development of compounds with proven bioavailability for the treatment of AD.
Witter
Daniel P
DP
The Scripps-Oxford Laboratory, Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK.
Chen
Yanping
Y
Rogel
Joseph K
JK
Boldt
Grant E
GE
Wentworth
Paul
P
D000544:Alzheimer Disease / Q000188:drug therapy; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D016466:CHO Cells; D002460:Cell Line; D006224:Cricetinae; D003412:Cricetulus; D047630:Depsipeptides / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D058225:Plaque, Amyloid / Q000378:metabolism
D016229:Amyloid beta-Peptides; D047630:Depsipeptides; C013833:beauverolides